CCND1 and non-small cell lung carcinoma: This is in accordance with the results in breast and non-small cell lung cancer cells by Kong et al., showing that resistance to CDK4/CDK6 inhibition via the induced feedback upregulation of Cyclin D1 and CDK4 is reversible using 3.2 nM of CR-1-31-B [37].